3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
3
Glioblastoma
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Malignant Solid Neoplasm
1
Kidney Neoplasms
1
Ischemic Stroke
1
Hypoxia
1
Hemorrhagic Stroke
1
Head and Neck Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Childhood Brain Neoplasm
1
Central Nervous System Vascular Malformations
1
Central Nervous System Infections
1
Carcinoma, Medullary
1
Cancer of Lymph Node
1
Interventions
Irinotecan
13
Cyclophosphamide
11
Vincristine
10
Filgrastim
10
Radiotherapy
9
Ifosfamide
9
Doxorubicin
9
Dactinomycin
7
Melphalan
6
Granulocyte Colony-Stimulating Factor
6
Etoposide
6
cixutumumab
5
Sirolimus
5
Peripheral Blood Stem Cell Transplantation
5
pegfilgrastim
4
Topotecan
4
Temozolomide
4
Radiation
4
Gemcitabine
4
Busulfan
4
temsirolimus
3
sargramostim
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
trioctyl phosphine oxide
2
regorafenib
2
olaparib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Rhabdomyosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts